Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
CSL Will Acquire Protein Firm Talecris
August 18, 2008
| A version of this story appeared in
Volume 86, Issue 33
Australian firm CSL is acquiring Talecris Biotherapeutics in Research Triangle Park, N.C., for $3.1 billion in cash, including $1.2 billion in debt. The combined company will have annual sales of about $4.5 billion and rank among the world’s largest providers of blood plasma-derived protein therapeutics and vaccines. Talecris was formed in 2005 by Cerberus Capital Management and Ampersand Ventures, which had acquired the former Bayer Plasma business for $590 million. In 2004, CSL bought a similar business, Aventis Behring, from Aventis for about $825 million.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X